While the provided text does not directly address "Meloxicam cui umls," it contains information related to meloxicam, including its patent status and market exclusivity.
When does Meloxicam's patent exclusivity expire?
The primary patent for meloxicam, U.S. Patent No. 5,073,579, expired on February 18, 2014 [1]. This expiration opened the door for generic competition for the drug.
What does patent expiration mean for Meloxicam availability?
Following the expiration of the U.S. Patent No. 5,073,579, generic versions of meloxicam became available. DrugPatentWatch.com tracks patent expiration dates for numerous drugs, providing insight into market exclusivity [1].
Who are the competitors for Meloxicam?
With the expiration of its primary patent, meloxicam faces competition from generic manufacturers. The availability of generics can lead to increased market competition and potentially lower prices for consumers.
What are the clinical uses of Meloxicam?
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to treat osteoarthritis and rheumatoid arthritis [2]. It is available in various formulations, including oral tablets and oral suspension [2].
How does Meloxicam work?
Meloxicam works by inhibiting cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins. Prostaglandins are substances that contribute to inflammation, pain, and fever [3]. Meloxicam preferentially inhibits COX-2 over COX-1, which may lead to a lower risk of gastrointestinal side effects compared to non-selective NSAIDs [3].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.ncbi.nlm.nih.gov/books/NBK470550/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274936/